Poly(adenosine diphosphate-ribose) polymerase inhibitors have recently been shown to be effective for patients with human epidermal growth factor receptor 2—negative (HER2−) advanced breast cancer (ABC) who have a germline mutation in their breast cancer susceptibility gene 1 or 2 (BRCA1/2mut). Here, ERBB2 is linked to breast carcinoma.